MRMarianna Pina Rambaldi

Marianna Pina Rambaldi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marianna Pina Rambaldi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • D4. MCA/UtA ratio at first observation is associated with birthweight in late onset IUGR

    by Serena Simeone, Marianna Pina Rambaldi, Caterina Serena, Serena Ottanelli, Federico Mecacci

    Introduction: MCA and uterine artery Doppler PI are commonly used in the evaluation of IUGR. Targets: This retrospective pilot study aims to investigate whether MCA/UtA ratio may identify adverse outcome in late onset IUGRs. A cohort of 69 pregnancies affected with late IUGR which underwent labor induction according to local protocols was retrospectively revised on the relationship between MCA/UtA ratio at first observation and the following adverse outcomes: cesarean section for nonreassuring fetal status, birthweight (expressed as percentile and continuous values, umbilical artery pH, NICU admission and Apgar score < 7 after 1 and 5 min. Results: The study population included 75.4% nulliparous women. Mean gestational age was 36.7 and 38.7 weeks’ gestation for diagnosis and induction, respectively. MCA/UtA ratio resulted significantly associated with a lower trend in birthweight, with a variation of 109.72 g for each unit considered (p = 0.040). The other outcomes considered showed no association. Conclusions: MCA/UtA ratio at first observation may be associated with lower birthweight in late onset IUGRs. Further prospective studies are expected.

  • Management of placental mesenchymal dysplasia associated with fetal anemia and IUGR

    by Serena Simeone, Chiara Franchi, Laura Marchi, Marianna Pina Rambaldi, Caterina Serena, Amerigo Vitagliano, Federico Mecacci


  • Inherited and Acquired Thrombophilias

    by Marianna Pina Rambaldi, Federico Mecacci, Secondo Guaschino, Michael J. Paidas

    Thrombophilias represent an evolving story that continues to stir controversy for care providers and obstetrical patients. The predominant thrombophilic mutations include the factor V Leiden mutation, prothrombin gene mutation G20210A, methylene tetrahydrafolate reductase C667T, and deficiencies of the natural anticoagulants proteins C and S, and antithrombin. Prospective cohort studies have provided an accurate assessment of the risk of placenta-mediated complications posed by common inherited thrombophilic conditions. Acquired thrombophilic conditions consist of the antiphospholipid antibody syndrome (APAS) and hyperhomocysteinemia. Well-conducted, placebo-controlled, randomized trials have demonstrated no benefit of anticoagulation in women with recurrent pregnancy loss and inherited thrombophilia. The routine use of anticoagulation to prevent other placenta-mediated complications in the setting of inherited thrombophilia should be considered experimental until the results of adequate clinical trials are available. Heparin anticoagulation and antiplatelet therapies are the cornerstone of treatment of APAS in pregnancy.